Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity.
The toxicity of netilmicin was compared with that of amikacin in a randomized, prospective trial in 90 adults with a variety of serious gram-negative infections. There was no instance of antibiotic-related nephrotoxicity in the group given amikacin and only one instance in the group given netilmicin. Cochlear toxicity, as measured by a change in audiogram, occurred in 4/14 (28.5%) of the amikacin recipients and 3/19 (15.8%) of the netilmicin recipients. Vestibular toxicity, as determined by a change in ice-water calorics, was noted in 3/16 (19%) of the amikacin-treated patients and 0/15 of the netilmicin-treated individuals. Despite the trend toward lesser ototoxicity with netilmicin, the differences between the drugs were not statistically significant. There was, however, a significant association between male sex and the development of ototoxicity. Although many patients could not be evaluated for efficacy, there did not appear to be any difference in the therapeutic activity of the two drugs.
D000368:Aged; D000583:Amikacin / Q000633:toxicity*; D001301:Audiometry, Pure-Tone; D001424:Bacterial Infections / Q000188:drug therapy; D002150:Caloric Tests; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D005260:Female; D005839:Gentamicins / Q000633:toxicity*; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000633:toxicity*; D011897:Random Allocation; D012737:Sex Factors; D014722:Vestibule, Labyrinth / Q000187:drug effects; D000159:Vestibulocochlear Nerve / Q000187:drug effects*
D005839:Gentamicins; D009428:Netilmicin; D007612:Kanamycin; D000583:Amikacin; D003404:Creatinine